Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$9.99 USD
-0.11 (-1.09%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $9.94 -0.05 (-0.50%) 7:56 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RAPT 9.99 -0.11(-1.09%)
Will RAPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RAPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RAPT
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why
RAPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for July 15th
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?
New Strong Buy Stocks for July 15th
Other News for RAPT
RAPT Therapeutics (RAPT) Receives Neutral Rating Upgrade by JP Morgan | RAPT Stock News
JPMorgan Adjusts Rapt Therapeutics (RAPT) Rating with New Price Target
Rapt Therapeutics just upgraded at JPMorgan, here's why
RAPT Receives Outperform Rating with Promising Market Potential | RAPT Stock News
LifeSci starts Rapt Therapeutics at Outperform on potential for lead asset